Media Summary: This webinar discussed how and when to work with FDA to improve your This presentation provides an overview of the Standard Khalid Eljaaly, PharmD, MS, CAPPS, BCPS, Contagion® Editorial Advisory Board member, postdoctoral research fellow on ...

Integrated Safety Analyses In Drug - Detailed Analysis & Overview

This webinar discussed how and when to work with FDA to improve your This presentation provides an overview of the Standard Khalid Eljaaly, PharmD, MS, CAPPS, BCPS, Contagion® Editorial Advisory Board member, postdoctoral research fellow on ... PHUSE FDA Data Science Innovation Challenge IC08 – Rajesh Krishna, Senior Director with IDD Certara, reflects on how decision This presentation identified FDA resources to assist with the Bio-IND process and provided an

The Hyve is thrilled to announce the webinar series "Beyond Traditional Approaches in FDA and multiple regulatory and industry members from the International Council for Harmonisation (ICH) E14/S7B ... Ever wondered how new medications are rigorously tested before they reach us? This video delves into the critical process of how ...

Photo Gallery

Integrated Safety Analyses in Drug Marketing Applications: Avoiding Common Mistakes
An Introduction to Integrated Summaries of Safety & Effectiveness
Advancing Premarket Safety Analytics Overview of the Standard Safety Tables/Figures Integrated Guide
Using Meta-Analysis to Study Drug Safety and Efficacy
IC08 – Drug Safety Surveillance – Datacise Integrated Safety Explorer
Keys to Success for Your Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE)
MIDD Training Module 4 – Case Study 1: Decision Analysis to Support Drug Development
CITI Program Webinar Demo - FDA IND Safety Reporting for Clinical Trial Investigations
CITC 2024 – D1S05 – Safety Considerations in Clinical Drug Development
GDF 2024 | D2S03-1 - Bio-IND Best Practices: An Analysis of Common Clinical Safety Hold and...
WEBINAR: Integrating Biomedical Ontologies with OMOP: Opportunities for Drug Safety Monitoring
New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment (1 of 2)
View Detailed Profile
Integrated Safety Analyses in Drug Marketing Applications: Avoiding Common Mistakes

Integrated Safety Analyses in Drug Marketing Applications: Avoiding Common Mistakes

This webinar discussed how and when to work with FDA to improve your

An Introduction to Integrated Summaries of Safety & Effectiveness

An Introduction to Integrated Summaries of Safety & Effectiveness

Integrated

Advancing Premarket Safety Analytics Overview of the Standard Safety Tables/Figures Integrated Guide

Advancing Premarket Safety Analytics Overview of the Standard Safety Tables/Figures Integrated Guide

This presentation provides an overview of the Standard

Using Meta-Analysis to Study Drug Safety and Efficacy

Using Meta-Analysis to Study Drug Safety and Efficacy

Khalid Eljaaly, PharmD, MS, CAPPS, BCPS, Contagion® Editorial Advisory Board member, postdoctoral research fellow on ...

IC08 – Drug Safety Surveillance – Datacise Integrated Safety Explorer

IC08 – Drug Safety Surveillance – Datacise Integrated Safety Explorer

PHUSE FDA Data Science Innovation Challenge IC08 –

Keys to Success for Your Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE)

Keys to Success for Your Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE)

The

MIDD Training Module 4 – Case Study 1: Decision Analysis to Support Drug Development

MIDD Training Module 4 – Case Study 1: Decision Analysis to Support Drug Development

Rajesh Krishna, Senior Director with IDD Certara, reflects on how decision

CITI Program Webinar Demo - FDA IND Safety Reporting for Clinical Trial Investigations

CITI Program Webinar Demo - FDA IND Safety Reporting for Clinical Trial Investigations

IND

CITC 2024 – D1S05 – Safety Considerations in Clinical Drug Development

CITC 2024 – D1S05 – Safety Considerations in Clinical Drug Development

Discover the critical

GDF 2024 | D2S03-1 - Bio-IND Best Practices: An Analysis of Common Clinical Safety Hold and...

GDF 2024 | D2S03-1 - Bio-IND Best Practices: An Analysis of Common Clinical Safety Hold and...

This presentation identified FDA resources to assist with the Bio-IND process and provided an

WEBINAR: Integrating Biomedical Ontologies with OMOP: Opportunities for Drug Safety Monitoring

WEBINAR: Integrating Biomedical Ontologies with OMOP: Opportunities for Drug Safety Monitoring

The Hyve is thrilled to announce the webinar series "Beyond Traditional Approaches in

New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment (1 of 2)

New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment (1 of 2)

FDA and multiple regulatory and industry members from the International Council for Harmonisation (ICH) E14/S7B ...

How Do Clinical Trials Determine Drug Safety?

How Do Clinical Trials Determine Drug Safety?

Ever wondered how new medications are rigorously tested before they reach us? This video delves into the critical process of how ...